Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Interventions
Vedolizumab Placebo
Vedolizumab
Locations
139
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
David Geffen School of Medicine at University of California Los Angeles
Los Angeles, California, United States
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
Augusta University Georgia Cancer Center
Augusta, Georgia, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States
Start Date
February 6, 2019
Primary Completion Date
February 7, 2022
Completion Date
May 9, 2022
Last Updated
June 6, 2023
NCT03136757
NCT02026934
NCT02073019
NCT00535548
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions